Which Is the Better Invesco Healthcare ETF: Equal-Weight RSPH or Biotech-Focused IBBQ?

The article contrasts two Invesco healthcare ETFs: Invesco Nasdaq Biotechnology (IBBQ) has a lower expense ratio of 0.19% vs 0.4% for Invesco S&P 500 Equal Weight Health Care (RSPH), but higher volatility (5Y max drawdown -37.9% vs -22.0%). IBBQ delivered a much stronger trailing 1-year return of 53.8% compared with 28.2% for RSPH, while both offer modest yields (0.8% for IBBQ vs 0.6% for RSPH). Based on the higher return/momentum in biotech and the cost advantage, the piece favors IBBQ as the more attractive buy for targeted biotech exposure despite the deeper drawdowns.

Analysis

This is less a fundamental call on healthcare than a vehicle-selection signal. The market is rewarding the cleaner biotech beta sleeve, but the important nuance is that IBBQ is not a pure early-stage lottery basket; its top weights are profitable large-cap names, so the downside profile is materially better than the word “biotech” implies. That makes it a relatively efficient way to own FDA/M&A optionality without taking as much clinical-binary risk as smaller-cap biotech proxies.

RSPH’s equal-weight structure is defensively constructed, but in a momentum-led tape it becomes a hidden headwind: it dilutes exposure to the names currently attracting capital and raises the influence of slower-moving healthcare tools/software/lab services. Over the next 1-3 months, the main catalyst is flow persistence rather than earnings; if biotech breadth stays healthy and capital remains willing to pay for pipeline and M&A optionality, IBBQ should keep taking share. If rates back up or risk appetite rolls over, IBBQ’s higher drawdown history will reassert itself fast.

The consensus is probably missing that the apparent fee advantage in IBBQ matters more than it looks because ETF selection is now a positioning decision, not just an expense-ratio decision. The contrarian risk is that the recent outperformance has already compressed the easy alpha: a lot of the good news is now in the multiple, and any disappointment from AMGN/VRTX/GILD would hit the whole basket because concentration is still meaningful. RSPH is the cleaner contrarian hedge if you expect a broad healthcare rotation into more stable, less momentum-sensitive exposure over 6-18 months.

Key Decisions for Investors

• Long IBBQ / short RSPH as a 6-12 week relative-value trade; enter on any 3-5% pullback in IBBQ or on a weak biotech tape. Target 8-10% relative outperformance; cut if RSPH outperforms for 2 straight weeks on improving breadth or if biotech ETF flows reverse.
• Use IBBQ as the preferred healthcare beta vehicle for a momentum book; the risk/reward is better than RSPH as long as FDA/M&A sentiment stays constructive over the next quarter.
• If you want a defensive healthcare exposure, prefer RSPH only as a hedge against a risk-off macro turn; otherwise avoid paying the higher fee for the slower-moving basket.
• Watch AMGN, VRTX, and GILD earnings/guidance as the falsifier for the IBBQ thesis: any pipeline disappointment or margin compression there would quickly unwind the ETF’s outperformance.